The Journal of Headache and Pain (Apr 2022)
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- Piero Barbanti,
- Gabriella Egeo,
- Cinzia Aurilia,
- Florindo d’Onofrio,
- Maria Albanese,
- Ilaria Cetta,
- Paola Di Fiore,
- Maurizio Zucco,
- Massimo Filippi,
- Francesco Bono,
- Claudia Altamura,
- Stefania Proietti,
- Stefano Bonassi,
- Fabrizio Vernieri,
- and for the FRIEND-Study Group
Affiliations
- Piero Barbanti
- Headache and Pain Unit, IRCCS San Rafaele Pisana
- Gabriella Egeo
- Headache and Pain Unit, IRCCS San Rafaele Pisana
- Cinzia Aurilia
- Headache and Pain Unit, IRCCS San Rafaele Pisana
- Florindo d’Onofrio
- Neurology Unit, San Giuseppe Moscati Hospital
- Maria Albanese
- Regional Referral Headache CenterNeurology Unit, University Hospital Tor Vergata
- Ilaria Cetta
- Headache Unit, Department of Neurology, Scientifc Institute San Rafaele Hospital, Vita-Salute University
- Paola Di Fiore
- Headache Center, ASST Santi Paolo Carlo
- Maurizio Zucco
- Headache Center, Neurlogy Unit, San Camillo-Forlanini Hospital
- Massimo Filippi
- Neurology Unit, IRCCS San Rafaele Scientifc Institute, Vita-Salute San Raffaele University
- Francesco Bono
- Center for Headache and Intracranial Pressure Disorders, Neurology Unit, A.O.U. Mater Domini
- Claudia Altamura
- Headache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico
- Stefania Proietti
- Clinical and Molecular Epidemiology, IRCCS San Rafaele
- Stefano Bonassi
- Clinical and Molecular Epidemiology, IRCCS San Rafaele
- Fabrizio Vernieri
- Headache and Neurosonology Unit, Campus BioMedico University Hospital
- and for the FRIEND-Study Group
- DOI
- https://doi.org/10.1186/s10194-022-01422-y
- Journal volume & issue
-
Vol. 23,
no. 1
pp. 1 – 1
Abstract
No abstracts available.